Oliveira Steven Michael
Known title: 10% OwnerCIK: 0001358629
Oliveira Steven Michael's purchase track record
Oliveira Steven Michael has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/9/2021 | BNTC | $32K | -23.8% | -68.4% | -13.9% |
| 11/29/2021 | BNTC | $121K | -27.0% | -67.0% | -11.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BNTC | ▲ Buy | Open Market | 10,553 | $32K | 12/9/2021 | View on chart |
| BNTC | ▲ Buy | Open Market | 37,947 | $121K | 11/29/2021 | View on chart |
| BNTC | ▲ Buy | Open Market | 40,500 | $172K | 5/3/2021 | View on chart |
| BNTC | ▲ Buy | Open Market | 120,000 | $502K | 4/30/2021 | View on chart |
| BNTC | ▲ Buy | Open Market | 22,877 | $126K | 4/29/2021 | View on chart |
| BNTC | ▲ Buy | Open Market | 100,000 | $545K | 4/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Benitec Biopharma shares fell 23.9% over four weeks
Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.
Benitec Biopharma shares fell 23.9% over four weeks. Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.